ROTH Capital Partners Acts as Sole Placement Agent for
Galectin Therapeutics Inc. (NASDAQ:GALT) in its
$9.8 Million Registered Direct

For more information please contact:

Investment Banking
John Chambers
Vice-Chairman and
Head of Healthcare
Investment Banking

(646) 358-1901
jchambers@roth.com


Michael Margolis, R.Ph
Managing Director
(646) 358-1902
mmargolis@roth.com

 

Warren Dunnavant II
Director
(646) 358-1903
wdunnavant@roth.com

Equity Capital Markets
Aaron Gurewitz
Head of Equity
Capital Markets
(949) 720-5703

agurewitz@roth.com

 

Nazan Akdeniz
Senior Vice President
(949) 720-5740

nakdeniz@roth.com

 

Lou Ellis
Senior Vice President
(949) 720-5739

lellis@roth.com

Transaction Information

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced it has completed a sale of 4,761,900 shares of common stock at a price of $2.06 per share and warrants to purchase up to 3,571,425 shares of common stock with an exercise price of $2.50 per share. Galectin intends to use the proceeds for clinical trial expenses, other research and development expenses, and for general corporate purposes.

 

ROTH Capital Partners acted as Sole Placement Agent for the offering.

 

About Galectin Therapeutics Inc.
Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer.  For more information, please visit www.galectintherapeutics.com. (Source: Company Press Release | 11/20/15)

 

About ROTH Capital Partners

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. For more information on ROTH, please visit www.roth.com.

About ROTH Investment Banking Venture Finance Institutional Sales & Trading
Research Corporate Services Marketing & Conferences Press Room

The material, information and  facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC ("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of ROTH. Copyright 2016.